• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Novartis' Kisqali cuts recurrence risk in early-stage breast cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 27, 2023 at 11:42: AM
via Topline data from the Phase III NATALEE study showed Novartis’ Kisqali (ribociclib) met its primary endpoint, reducing the risk of recurrence in early breast cancer, the company announced Monday.

article source
 




Top Bottom
Back
Quote